Inflexion backed the buyout of TMF services provider Phlexglobal in 2011, supporting succession and international growth. In 2014 the firm was sold to Bridgepoint Development Capital, generating a 2.8x return on investment.

  • Sector


  • Headquarters

    Buckinghamshire, UK

  • Fund


  • Investment date

    March 2011 - July 2014

  • Status



The company

Established in 1997, Phlexglobal is a specialist provider of tech-enabled TMF document management solutions to the global clinical research market. A TMF is the collection of all essential documents required to demonstrate compliance with the regulatory requirements for clinical trials. In 2006, Phlexglobal developed its own electronic system, PhlexEview, which, combined with the related business processes of scanning and archiving, is the principal solution of the business.

The business employs around 200 people in the UK and US, and counts a significant majority of the top 20 global pharmaceutical companies among its clients.

The Inflexion investment

Inflexion led the management buyout of the business in March 2011.

The Inflexion difference

Inflexion’s investment allowed the founder to transition out of the business, and provided an opportunity to strengthen the management team with the appointment of a CEO and CTO. Working together, management and Inflexion then rapidly expanded international operations, opening a new office in Pennsylvania in the US to target North American pharma clients, and assessing the opportunity in India and Asia Pacific through Inflexion’s in-country experts. Phlexglobal also accelerated investment in its core technology platform and its service provision.

Press releases